Journal of the European Academy of Dermatology and Venereology最新文献

{"title":"Rifampicin and clindamycin for epidermal growth factor receptor inhibitor-related acneiform rash.","authors":"Giovanni Paolino, Dario Didona","doi":"10.1111/jdv.20688","DOIUrl":"https://doi.org/10.1111/jdv.20688","url":null,"abstract":"","PeriodicalId":17351,"journal":{"name":"Journal of the European Academy of Dermatology and Venereology","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2025-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143795958","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Forehead burns following Ash Wednesday rituals: A retrospective observational analysis.","authors":"Joe Khodeir, Paul Ohanian, Lynn Daoud, Dima Jeha, Maya Habre","doi":"10.1111/jdv.20689","DOIUrl":"https://doi.org/10.1111/jdv.20689","url":null,"abstract":"","PeriodicalId":17351,"journal":{"name":"Journal of the European Academy of Dermatology and Venereology","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2025-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143795955","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cutaneous lupus matters: Independent and additive quality-of-life burden shown by 2022 WLFGI Survey.","authors":"Arianna J Zhang, Nnenna Ezeh, Beth Childs, Subrina Farah, Joy Buie, Mike Donnelly, Daria McClamb, Lydia Oberholtzer, Jana Sharp, Joseph F Merola","doi":"10.1111/jdv.20646","DOIUrl":"https://doi.org/10.1111/jdv.20646","url":null,"abstract":"","PeriodicalId":17351,"journal":{"name":"Journal of the European Academy of Dermatology and Venereology","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2025-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143795953","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Survival after cessation of immunotherapies in melanoma: A systematic review and meta-analysis.","authors":"Kristine E Mayer, Lydia Warburton, Anne Zaremba, Sarah Preis, Yannick Foerster, Tilo Biedermann, Oana-Diana Persa","doi":"10.1111/jdv.20672","DOIUrl":"https://doi.org/10.1111/jdv.20672","url":null,"abstract":"<p><strong>Background: </strong>Immune-checkpoint inhibitor (ICI) therapy elicits durable responses in a subset of patients with advanced melanoma. However, the appropriate timing for treatment cessation remains an unresolved issue. Moreover, some patients are required to discontinue therapy due to the occurrence of severe adverse events. Upon treatment cessation, a subset of patients maintains a durable response, while some patients relapse and require rechallenge with ICI. Criteria for a safe stop of ICI have not been established.</p><p><strong>Objectives: </strong>The aim of this systematic review and meta-analysis was to evaluate the durability of response in melanoma patients who discontinued ICI therapy. Furthermore, the outcome of patients who electively stopped therapy was compared to that of patients who discontinued therapy due to adverse events.</p><p><strong>Methods: </strong>MEDLINE/PubMed, Embase and the Cochrane Library were searched for studies reporting outcomes after ICI discontinuation in patients with advanced melanoma. Pooled 1- to 3-year progression-free survival (PFS) and overall survival (OS) rates were estimated using random-effects models. The impact of the reason for treatment discontinuation, therapy regime and treatment duration on relapse-free survival was evaluated.</p><p><strong>Results: </strong>Twenty studies including 1832 patients were analysed. The pooled 1- and 3-year PFS rates after therapy stop were 86% (95% CI 80%-91%) and 71% (95% CI 64%-77%). A significantly higher 1-year PFS rate was observed in patients who electively discontinued treatment in contrast to toxicity-related therapy cessation (91% vs. 79%). Longer ICI treatment was associated with a higher PFS rate. 1- and 3-year OS rates post ICI treatment discontinuation were 96% (95% CI 91%-99%) and 86% (95% CI 79%-92%).</p><p><strong>Conclusions: </strong>Most patients remained relapse-free after ICI treatment. Patients with a treatment duration of at least 2 years are ideal candidates for treatment cessation, while treatment discontinuation may be considered after at least 1 year of ICI. PROSPERO number: CRD42024543781.</p>","PeriodicalId":17351,"journal":{"name":"Journal of the European Academy of Dermatology and Venereology","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2025-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143780377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Venous thromboembolic events in patients treated with Janus kinase inhibitors for atopic dermatitis.","authors":"Catherine Droitcourt, Sandrine Kerbrat, Delphine Staumont-Salle, Alain Lescoat, Emmanuel Oger, Lucie-Marie Scailteux","doi":"10.1111/jdv.20682","DOIUrl":"https://doi.org/10.1111/jdv.20682","url":null,"abstract":"","PeriodicalId":17351,"journal":{"name":"Journal of the European Academy of Dermatology and Venereology","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143772644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Infection risk in atopic dermatitis patients treated with biologics and JAK inhibitors: BioDay results.","authors":"Lian F van der Gang, Keneshka Atash, Nicolaas P A Zuithoff, Inge Haeck, Celeste M Boesjes, Octavian I Bacoş-Cosma, Laura Loman, Marijke Kamsteeg, Simone Stadhouders-Keet, Albert J Oosting, Anneke M T van Lynden-van Nes, Klaziena Politiek, Antoni Gostynksi, Lisette Berntsen-Zandbergen, Wianda A Christoffers, Annebeth Flinterman, Wouter R H Touwslager, Berit Velstra, Shiarra M Stewart, Francine C van Erp, Marlies de Graaf, Marie-Louise A Schuttelaar, Marjolein S de Bruin-Weller","doi":"10.1111/jdv.20674","DOIUrl":"https://doi.org/10.1111/jdv.20674","url":null,"abstract":"<p><strong>Background: </strong>Limited data exist on the comparative risk of infections during biologic and Janus kinase inhibitor (JAKi) treatment for atopic dermatitis (AD) in daily practice.</p><p><strong>Objective: </strong>To assess the differential infection risk of biologic and JAKi treatment in patients with moderate-to-severe AD in a real-world setting.</p><p><strong>Methods: </strong>This prospective, multicentre study evaluated treatment-emergent infections in patients (age ≥ 12 years) using biologics or JAKi from the BioDay registry from October 2017 to July 2024. Crude incidence rates were calculated per 100 patient-years (PY) per treatment. Cox regression for recurrent events, adjusted for potential confounders, was used to estimate hazard ratios (HR) for the rate of infections, with subgroup and sensitivity analyses in bio-/JAKi-naïve patients.</p><p><strong>Results: </strong>In total 1793 patients were included (4044.1 PY; 1886 biologic treatment episodes (TEs); 480 JAKi), with 794 infections. JAKi showed higher infection rates (58.4-65.5/100 PY) compared to biologics (13.6-22.0), especially for herpes infections (n = 195, 24.6%; JAKi 13.6-19.8 vs. biologicals 3.0-3.6). Cox regression indicated increased rates with JAKi (abrocitinib HR 4.1, 95% CI: 3.1-5.5; baricitinib HR 4.2, 95% CI: 2.9-6.2; upadacitinib HR 4.0, 95% CI: 3.2-5.0; all p < 0.0001) and a slight increase with tralokinumab (HR 1.4, 95% CI: 1.0-2.0, p = 0.039) compared to dupilumab. Sensitivity analyses confirmed these results, except for tralokinumab. Rates of severe infections were higher with JAKi compared to dupilumab, although absolute numbers were low and associations were not consistently significant. History of infection, predominantly viral or fungal skin infections (HR 1.9, 95% CI: 1.4-2.6, p < 0.0001; 2.4, 1.3-4.4, p = 0.003, resp.), was identified as an independent factor associated with infection.</p><p><strong>Conclusion: </strong>This cohort study demonstrated an increased risk of infection during JAKi treatment compared to dupilumab for moderate-to-severe AD. These findings enhance understanding of the differential infection risk with targeted therapies in AD, aiding tailored treatment choices that consider patient-specific risks such as prior skin infections.</p>","PeriodicalId":17351,"journal":{"name":"Journal of the European Academy of Dermatology and Venereology","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143772632","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Defining surgical margins for lentigo maligna with line-field confocal optical coherence tomography.","authors":"Juliette Archimbaud, Clothilde Raoux, Kevin Serror, Camille Gandon, Maxime Battistella, Céleste Lebbé, Barouyr Baroudjian","doi":"10.1111/jdv.20680","DOIUrl":"https://doi.org/10.1111/jdv.20680","url":null,"abstract":"","PeriodicalId":17351,"journal":{"name":"Journal of the European Academy of Dermatology and Venereology","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143772629","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"NLRP3 missense variant may contribute to dermatophytosis susceptibility.","authors":"Gabriela Blanchard, Maël Blanchard, Pacôme Prompsy, Marina Fratti, Ioannis Xenarios, Arkadiy Shevrikuko, Karine Salamin, Michel Monod, Emmanuella Guenova","doi":"10.1111/jdv.20658","DOIUrl":"https://doi.org/10.1111/jdv.20658","url":null,"abstract":"","PeriodicalId":17351,"journal":{"name":"Journal of the European Academy of Dermatology and Venereology","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143772640","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characterizing pigmented mucosal lesions: New insights from reflectance confocal microscopy.","authors":"Mario Valenti, Francesco Piscazzi, Chiara Franceschini, Angela Ferrari, Pasquale Frascione, Marco Ardigò","doi":"10.1111/jdv.20656","DOIUrl":"https://doi.org/10.1111/jdv.20656","url":null,"abstract":"","PeriodicalId":17351,"journal":{"name":"Journal of the European Academy of Dermatology and Venereology","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2025-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143764275","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"YAP1-NUTM1 fusions are infrequent in porocarcinomas arising in a cohort including immunocompromised patients.","authors":"Mark Eisner, Remus Winn, Tom Oliphant, Miguel Joao Xavier, Akhtar Husain, Catherine A Harwood, Neil Rajan","doi":"10.1111/jdv.20681","DOIUrl":"https://doi.org/10.1111/jdv.20681","url":null,"abstract":"","PeriodicalId":17351,"journal":{"name":"Journal of the European Academy of Dermatology and Venereology","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2025-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143764287","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}